Webinar Provides Details on COMPASS PWS Clinical Trial
Acadia Pharmaceuticals' COMPASS-PWS Clinical trial, enrolling PWS patients aged 5-30 with hyperphagia, aims to evaluate carbetocin's safety and efficacy via nasal spray. The phase 3 study involves 170 participants in a double-blind setup, with key eligibility criteria including no recent food interventions or treatment studies. The trial includes 5 clinic visits and an optional 3-year open-label extension. For details, visit compasspws.com.
Highlighted Terms
Related News
Acadia Pharmaceuticals' COMPASS-PWS Clinical trial, enrolling PWS patients aged 5-30 with hyperphagia, aims to evaluate carbetocin's safety and efficacy via nasal spray. The phase 3 study involves 170 participants in a double-blind setup, with key eligibility criteria including no recent food interventions or treatment studies. The trial includes 5 clinic visits and an optional 3-year open-label extension. For details, visit compasspws.com.